VRAX — VIRAX BIOLABS GROUP LTD
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Wall Street Analyst Consensus
Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19
Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 4 SEC-registered investment managers reported holding VRAX (VIRAX BIOLABS GROUP LTD) in their latest 13F filings, with a combined reported value of $72.43K across 33.16K shares. That is +25.7% by share count (+6.77K shares) versus the previous quarter, while reported value moved -6.7%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 2 opened new positions, 2 added to existing stakes. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of VIRAX BIOLABS GROUP LTD (VRAX) include Renaissance Technologies, ARMISTICE CAPITAL, LLC, Squarepoint Ops LLC, ranked by reported 13F value among the 28 institutional holders on this page.
VRAX is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 4 | 33.16K | $72.43K | +25.7% |
| Q2 2026 | 2 | 26.39K | $77.58K | — |
| Q1 2026 | 4 | 919.57K | $202.21K | +0.0% |
| Q4 2025 | 6 | 34.98K | $12.09K | +1.0% |
| Q3 2025 | 5 | 94.83K | $57.06K | +100.0% |
| Q2 2025 | 2 | 35.16K | $28.62K | +122.7% |
| Q1 2025 | 4 | 63.10K | $71.53K | -40.9% |
| Q4 2024 | 7 | 63.01K | $141.37K | +84.7% |
Over the 8 quarters shown, institutional share counts decreased 47% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q2 2025 (+122.7%).
Top Institutional Holders (Q3 2026) — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 32.90K | $71.86K | 0.00% | Add | |
| 257 | $561 | 0.00% | Add | |
| 3 | $7 | 0.00% | New | |
| 2 | $4 | 0.00% | New |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 2 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 26.39K | $77.57K | 0.00% | New | |
| 4 | $12 | 0.00% | New |
Q1 2026 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 878.80K | $193.25K | 0.00% | New | |
| 40.72K | $8.96K | 0.00% | New | |
| 21 | $4 | 0.00% | Hold | |
| 20 | $4 | 0.00% | Hold |
Q4 2025 — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 21.44K | $7.41K | 0.00% | New | |
| 7.49K | $2.59K | 0.00% | Add | |
| 6.00K | $2.07K | 0.00% | Reduce | |
| 21 | $7 | 0.00% | Hold | |
| 20 | $7 | 0.00% | New | |
| 10 | $3 | 0.00% | New |
Q3 2025 — 5 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 60.07K | $36.00K | 0.00% | New | |
| 21.38K | $13.00K | 0.00% | New | |
| 10.00K | $6.00K | 0.00% | Add | |
| 3.36K | $2.04K | 0.00% | New | |
| 21 | $13 | 0.00% | New |
Q2 2025 — 2 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 30.16K | $24.67K | 0.00% | Add | |
| 5.00K | $3.95K | 0.00% | New |
New Positions (Q3 2026)
- Caitong International Asset Management Co., Ltd 3 sh · $7
- JPMorgan Chase & Co 2 sh · $4
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JANE STREET GROUP, LLC | 32.90K | 26.39K | — | — | — | — | — | — | 11.63K | — | — | — | — | — | — | — | — |
| UBS Group AG | 257 | 4 | — | 7.49K | 3.36K | — | 22.43K | 37.91K | 20.53K | 5.60K | 2.58K | 665 | 147 | — | 3.07K | 6.18K | 12.20K |
| Caitong International Asset Management Co., Ltd | 3 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| JPMorgan Chase & Co | 2 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Renaissance Technologies | — | — | — | — | — | — | — | — | 145.40K | 11.00K | — | — | — | 24.60K | — | 11.40K | — |
| ARMISTICE CAPITAL, LLC | — | — | 878.80K | — | — | — | — | — | — | — | — | 122.00K | — | — | — | — | — |
| Squarepoint Ops LLC | — | — | — | — | — | — | — | — | 40.62K | — | — | — | — | — | — | — | — |
| Legal & General Investment Management America | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 99.76K | 102.61K | — |
| HRT FINANCIAL LP | — | — | — | — | 60.07K | — | 13.51K | — | — | 25.67K | — | — | — | — | — | — | — |
| Virtu Financial LLC | — | — | — | — | 21.38K | — | — | — | — | 28.06K | — | 10.64K | — | — | — | — | — |
| XTX Topco Ltd | — | — | — | 21.44K | — | — | — | 11.86K | — | — | — | — | — | — | — | — | — |
| Citadel Advisors | — | — | — | — | — | 30.16K | 13.54K | — | — | — | 14.79K | — | 16.36K | — | — | — | — |
| ROYAL BANK OF CANADA | — | — | — | — | — | — | — | 10.40K | — | — | — | — | — | — | — | — | — |
| TWO SIGMA SECURITIES, LLC | — | — | — | — | — | — | 13.63K | — | — | — | — | — | — | — | — | — | — |
| Jump Financial, LLC | — | — | 40.72K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| R Squared Ltd | — | — | — | — | — | — | — | 2.70K | — | — | — | — | — | — | — | — | — |
| NATIONAL BANK OF CANADA /FI/ | — | — | — | 6.00K | 10.00K | 5.00K | — | — | — | — | — | — | — | — | — | — | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | — | — | — | — | — | — | — | — | — | — | — | — | 15.00K | — | — | — | — |
| Wells Fargo & Co | — | — | — | — | — | — | — | — | — | 100 | 100 | 200 | 2.00K | 2.00K | — | — | — |
| Headlands Technologies LLC | — | — | — | — | — | — | — | — | 185 | 45 | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold VRAX?
As of 2026-Q3, 4 institutional funds reported holding VRAX (VIRAX BIOLABS GROUP LTD) in SEC 13F filings, with a combined reported value of $72.43K.
How many shares of VRAX do institutions own?
13F filers reported 33.16K shares of VRAX, worth $72.43K in aggregate at the end of 2026-Q3.
Is institutional ownership of VRAX rising or falling?
Share counts moved +25.7% versus the prior quarter — accumulation.
Who are the top institutional holders of VRAX?
The largest 13F holders are Renaissance Technologies, ARMISTICE CAPITAL, LLC, Squarepoint Ops LLC, JANE STREET GROUP, LLC, Legal & General Investment Management America; the top 25 are ranked at the top of this page.
Who are the major shareholders of VIRAX BIOLABS GROUP LTD?
The major shareholders of VIRAX BIOLABS GROUP LTD (VRAX) by reported 13F value are Renaissance Technologies, ARMISTICE CAPITAL, LLC, Squarepoint Ops LLC, JANE STREET GROUP, LLC, Legal & General Investment Management America, among 28 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.